Cargando…

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis

Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the ‘benefits’ are not yet in relation to these...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Amerongen, Rosa A, Retèl, Valesca P, Coupé, Veerle MH, Nederlof, Petra M, Vogel, Maartje J, van Harten, Wim H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102690/ https://www.ncbi.nlm.nih.gov/pubmed/27899957 http://dx.doi.org/10.3332/ecancer.2016.684

Ejemplares similares

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
por: Verbeek, Joost G. E., et al.
Publicado: (2019)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology
por: Joosten, S.E.P., et al.
Publicado: (2016)

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
por: Lindenberg, Melanie A., et al.
Publicado: (2022)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
por: Retèl, Valesca P, et al.
Publicado: (2011)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients
por: Jansen, Femke, et al.
Publicado: (2016)

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
por: Simons, Martijn J. H. G., et al.
Publicado: (2021)

Association between genomic recurrence risk and well-being among breast cancer patients
por: Retèl, Valesca P, et al.
Publicado: (2013)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
por: Verbeek, Joost G. E., et al.
Publicado: (2023)

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation
por: van Harten, WH, et al.
Publicado: (2016)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Cost-effectiveness of the SEN-concept: Specialized Emergency Nurses (SEN) treating ankle/foot injuries
por: Derksen, Robert J, et al.
Publicado: (2007)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

Budget impact analysis of providing hospital inpatient care at home virtually, starting with two specific surgical patient groups
por: Peters, Guido M, et al.
Publicado: (2022)

Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries
por: Mewes, Janne C., et al.
Publicado: (2015)

Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison
por: Wolff, Henri B., et al.
Publicado: (2022)

Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists
por: Byng, Danalyn, et al.
Publicado: (2021)

The cumulative false-positive rate in colorectal cancer screening: a Markov analysis
por: Haug, Ulrike, et al.
Publicado: (2020)

Working with Costs and Budgets
por: Institute of Leadership, et al.
Publicado: (2013)

Next Step in Cost Containment of Public Hospital Economy Could Be Merging of Anesthesia and Surgery Budgets
por: Rosenberg, Jacob, et al.
Publicado: (2016)

The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
por: van Delft, Frederik, et al.
Publicado: (2020)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Prevalence of adjustment disorder among cancer patients, and the reach, effectiveness, cost-utility and budget impact of tailored psychological treatment: study protocol of a randomized controlled trial
por: van Beek, Florie E., et al.
Publicado: (2019)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
por: Hirsh, Vera
Publicado: (2015)

Tumor molecular profiling of NSCLC patients using next generation sequencing
por: Tsoulos, Nikolaos, et al.
Publicado: (2017)

Cost effectiveness and budget impact of universal varicella vaccination in Russia
por: Marijam, Alen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h514icifqgqne67ntj72lvrod2